Држава: Ирска
Језик: Енглески
Извор: HPRA (Health Products Regulatory Authority)
Human albumin macro aggregated
CIS bio International
B05AA; B05AA01
Human albumin macro aggregated
2.0 milligram(s)
Kit for radiopharmaceutical preparation
Product subject to prescription which may not be renewed (A)
Blood substitutes and plasma protein fractions; albumin
Marketed
2001-10-19
Health Products Regulatory Authority 18 December 2019 CRN008R54 Page 1 of 16 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT PULMOCIS 2 mg kit for radiopharmaceutical preparation 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 2 mg macroaggregated human albumin (macrosalb). The macroaggregates number per vial is ranging between 2 x 10 6 and 4 x 10 6 . In the labelled product the particle size distribution is as follows: more than 95 % of the particles are between 10 and 100 micrometers. No macroaggregates has a size larger than 150 micrometer. Produced from human serum albumin of human donors. The radionuclide is not part of the kit. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Kit for radiopharmaceutical preparation. White powder in pellet form. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS This medical product is for diagnostic use only. After radiolabelling with sodium pertechnetate ( 99m Tc) solution, the suspension of technetium ( 99m Tc)‑albumin macroaggregates obtained is indicated in adults and paediatric population for: Pulmonary perfusion scintigraphy For the diagnosis or exclusion of pulmonary embolism in patients with symptoms of pulmonary embolism and for monitoring the evolution of a pulmonary embolism; For examinations concomitant to therapies that result in a significant reduction in the regional lung perfusion, as preoperative investigation of local pulmonary perfusion prior to (partial) lung resection, preoperative examination and progress monitoring of lung transplants and for pre-therapeutic examinations for assisting radiation therapy planning; In combination with ventilation scintigraphy for the initial evaluation and the follow-up of patients with severe obstructive and/or restrictive pulmonary diseases; For the diagnosis and quantification of pulmonary right-to-left shunts. Radionuclide venography As an alternative to Doppler ultrasound, for radionuclide venography of the lower limbs, in combination with pulmonary p Прочитајте комплетан документ